Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Grant Kim_2023
Grant Kim Shares His Views from the Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Achieving All Three Primary Endpoints
Shots: Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…
September 19, 2023
VIEWPOINTS_Simon Portsmouth_2023
Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
Shots: Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection He mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…
September 18, 2023
VIEWPOINTS_Michael Jones_2023
Michael Jones Shares his Views on the Closing of Acquisition of Apollo Endosurgery
Shots: Michael discussed the closure of its acquisition of Apollo Endosurgery. He emphasized how this acquisition will broaden Boston Scientific's ELS portfolio, particularly in closure and suturing, while entering the endobariatric market He also talked about how the Apollo Endosurgery products will be integrated into Boston Scientific's existing endoluminal surgery (ELS) portfolio The interview shows…
September 4, 2023
VIEWPOINTS_Eli Khankin_2023
Eli Khankin Shares Update on the P-III IMAGINE Study Protocol Published in American Journal of Transplantation
Shots: Eli spoke about the P-III IMAGINE study protocol evaluating Clazakizumab along with 6 articles by several experts published in the American Journal of Transplantation Eli then talked about Clazakizumab's potential mechanism of action currently under investigation The interview shows how CSL Behring works to develop and deliver innovative therapies for people living with conditions in…
August 31, 2023
VIEWPOINTS_Curtis Rambaran_2023
Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events
Shots: Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluated He also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…
August 28, 2023
VIEWPOINTS_Dr. Beth McQuiston_2023
Dr. Beth McQuiston Shares her Views on the US FDA Clearance of the First Concussion Blood Test Available for Lab Instruments
Shots: Dr. Beth discussed traumatic brain injuries (TBIs) and the new TBI blood test by Abbott. She told PharmaShots how this blood test measures specific biomarkers, offering objective results within 12 hours, and aiding in evaluating suspected mild TBIs She also talked about how Abbott’s Alinity i lab technology facilitates swift testing, complementing Abbott's i-STAT…
August 21, 2023
Load more